The research information on using atropine for myopia control is evolving. Previous research indicated 0.01% atropine was best, but newer research says otherwise. In this clinical case, practitioners discuss treatment strategies, which are put in research context with clinical pearls for practice.
Atropine can be used for myopia control as a monotherapy or as an adjunct to an optical intervention – we discuss patient selection, atropine combination treatments, how to taper and when to stop.
Adult myopia progression is frequently encountered in practice, yet we have almost no evidence base to guide management. Here we explore how often and how much myopia progression occurs in adulthood, and management options.
Myopia control treatments can be tapered or stopped when it appears myopia progression is stabilizing.When should you stop myopia control treatments?
HWN presented this case involving a 32-year-old woman whose myopia onset after having her first child and had progressed since.
Children with more than 5-6D of myopia can require special consideration to ensure safe management of their ocular and systemic health. This clinical case details important aspects of care for the very high childhood myope: ophthalmology co-management, best optical corrections, parental education and eye health monitoring.
Myopia progression graphs, tools and apps are an excellent visual display. But how reliable are these calculators for your patient?
Welcome to the final instalment of myopia content from the American Academy of Optometry 2019 meeting. These updates continue from Part 2, which detailed Mark Bullimore and Noel Brennan’s fantastic session entitled Twelve Evidence Based Things That We Should Know About Myopia.
AAO2019 Meeting and third biannual World Congress of Optometry– Addressing the global myopia burden: guest summary by Sally Dillehay.
The latest from the Global Specialty Lens Symposium 2020 (GSLS2020) on research, intervention updates and young adult myopia progression.
